| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.1 - Asymptomatic | 2014 | Spain | IgE | 50 | 0.000 | 20140625, Armentia A
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Belgium | IgE | 86 | 15.110 | 20101214, Gadisseur R
| | 1.10 - Any allergy symptom, Diagnosed | 2014 | Brazil | IgE | 34 | 55.900 | 20141118, Santiago HD
| | 1.10 - Any allergy symptom, Diagnosed | 2014 | Brazil | IgE | 30 | 33.300 | 20141118, Santiago HD
| | 1.10 - Any allergy symptom, Diagnosed | 2010 | Italy | IgE | 16408 | 20.720 | 20100301, Scala E
| | 1.11 - Esophagitis, Diagnosed | 2013 | Netherlands | IgE | 76 | 21.100 | 20131020, van Rhijn BD
| | 1.11 - Esophagitis, Diagnosed | 2014 | Spain | IgE | 67 | 4.500 | 20140625, Armentia A
| | 1.11 - Esophagitis, Diagnosed | 2013 | Switzerland | IgE | 35 | 51.430 | 20130605, Simon D
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 18.750 | 20120528, Patelis A
| | 1.5 - Atopic Dermatitis, Diagnosed | 2013 | Germany | IgE | 140 | 17.140 | 20130111, Ott H
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 25.000 | 20091005, Ott H
| | 1.9 - Pollen Allergy | 2014 | Czech Republic | IgE | 826 | 28.700 | 20140606, Panzner P
| | 1.9 - Pollen Allergy | 2014 | Spain | IgE | 50 | 32.000 | 20140625, Armentia A
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 3.1.1 - Source Sensitized (SPT) | 2003 | Italy | IgE | 749 | 54.900 | | | 3.1.4 - Source Sensitized (SPT, IgE) | 2001 | Italy | IgE | 77 | 67.500 | | | 3.2.1 - Source Sensitized (IgE) | 2003 | Austria | IgE | 25 | 68.000 | | | 3.2.1 - Source Sensitized (IgE) | 2005 | Finland | IgE | 57 | 28.000 | | | 3.2.1 - Source Sensitized (IgE) | 2002 | Not Defined | IgE | 184 | 56.000 | | | 3.2.1 - Source Sensitized (IgE) | 2000 | Not Defined | IgE | 306 | 59.800 | | | 3.2.1 - Source Sensitized (IgE) | 2005 | Russian Federation | IgE | 12 | 0.000 | | | 3.2.1 - Source Sensitized (IgE) | 2003 | Zimbabwe | IgE | 25 | 0.000 | | | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Austria | IgE | 54 | 29.600 | 20120310, Twaroch TE
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 13.640 | 20091121, Ebo DG
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2012 | Italy | IgE | 26 | 50.000 | 20120310, Twaroch TE
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 70.000 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 48.640 | 20090826, Ebo DG
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Austria | IgE | 29 | 69.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Canada | IgE | 15 | 20.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Denmark | IgE | 26 | 77.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | France | IgE | 38 | 58.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Japan | IgE | 20 | 10.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 2014 | Spain | IgE | 103 | 56.200 | 20141003, Beitia JM
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 2011 | Spain | IgE | 43 | 62.800 | 20110713, Cabrera-Freitag P
| | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Sweden | IgE | 35 | 34.000 | | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1996 | Switzerland | IgE | 20 | 30.000 | | | 5.3.1 - Source Exposed (Symptoms, IgE) | 1994 | Austria | IgE | 30 | 60.000 | | | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 34.340 | 20110223, De Knop KJ
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Germany | IgE | 101 | 57.420 | 20140306, Darsow U
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 37 | 11.000 | 20140127, Konradsen JR
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | Sweden | IgE | 28 | 18.000 | 20140127, Konradsen JR
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2006 | Germany | IgE (IB) | 70 | 57.100 | 20060602, Petersen A
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Austria | IgE | 49 | 53.000 | 20131014, Bokanovic D
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Austria | IgE | 49 | 53.000 | 20131014, Bokanovic D
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2013 | Austria | IgE | 49 | 49.000 | 20131014, Bokanovic D
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Austria | IgE | 82 | 82.900 | 20080314, Westritschnig K
| | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2000 | Italy | IgE | 276 | 86.900 | | | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 1993 | Austria | IgE (IB) | 98 | 62.000 | | | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2008 | Austria | SPT | 82 | 59.750 | 20080314, Westritschnig K
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 3.770 | 20120528, Patelis A
|
|
Loading...
Phl p 2
